Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fish and Richardson
Covington
Farmers Insurance
Chinese Patent Office
Johnson and Johnson
Teva
Federal Trade Commission
Colorcon

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

« Back to Dashboard

Clinical Trials for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58

Trial ID Title Status Sponsor Phase Summary
NCT00004495 Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis Completed Georgetown University N/A OBJECTIVES: I. Compare the efficacy of two doses of folic acid in normalizing plasma total homocysteine concentration in patients with end stage renal disease receiving regular hemodialysis therapy resulting in hyperhomocysteinemia. II. Determine the requirement of co-supplementation with extra pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) daily in these patients. III. Assess the safety and tolerability of this therapy in these patients.
NCT00004734 Vitamin Therapy for Prevention of Stroke Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 3 A stroke occurs when part of the brain is damaged from lack of normal blood supply. This may result in difficulty with feeling, speech, muscle strength or coordination, movement, thinking, or other brain functions. Having a stroke increases the risk of another stroke occurring in the future. Higher blood levels of a natural chemical known as homocysteine may contribute to hardening of the arteries in the brain or heart and increase the risk of stroke or heart attack. Folic acid, vitamin B6 (pyridoxine), and vitamin B12 (cyanocobalamin) may lower blood levels of homocysteine and reduce the risk of having another stroke or a heart attack.
NCT00032435 Homocysteine Study (HOST) Completed Abbott Diagnostics Division Phase 3 The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00032435 Homocysteine Study (HOST) Completed Pan American Laboratories Phase 3 The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00032435 Homocysteine Study (HOST) Completed VA Office of Research and Development Phase 3 The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58

Condition Name

Condition Name for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58
Intervention Trials
Anaemia 2
Vitamin B12 Deficiency 2
End Stage Renal Disease 2
Stroke 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58
Intervention Trials
Vitamin B 12 Deficiency 3
Kidney Diseases 2
Kidney Failure, Chronic 2
Brain Edema 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58

Trials by Country

Trials by Country for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58
Location Trials
United States 139
India 2
Korea, Republic of 1
Italy 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58
Location Trials
Ohio 9
Illinois 8
Pennsylvania 8
Texas 7
North Carolina 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58

Clinical Trial Phase

Clinical Trial Phase for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 11
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58
Clinical Trial Phase Trials
Completed 17
Terminated 2
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58

Sponsor Name

Sponsor Name for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58
Sponsor Trials
National Cancer Institute (NCI) 8
Gynecologic Oncology Group 4
Eastern Cooperative Oncology Group 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cyanocobalamin; Cyanocobalamin Co-57; Cyanocobalamin Co-58
Sponsor Trials
Other 21
NIH 9
Industry 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
US Department of Justice
McKesson
Mallinckrodt
AstraZeneca
Cerilliant
Healthtrust
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.